Teva to Present at the 6th Annual Evercore ISI HealthCONx Conference
20 Novembro 2023 - 6:30PM
Business Wire
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today
announced that Richard Francis, Teva's President and CEO, will
present at the Evercore ISI HealthCONx Conference on Tuesday,
November 28, 2023. The presentation will begin at 8:20 A.M. Eastern
Time.
To access a live webcast of the presentation, visit Teva’s
Investor Relations website at
https://ir.tevapharm.com/Events-and-Presentations.
An archived version of the webcast will be available within 24
hours after the end of the live discussion and will be accessible
for up to 90 days.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has
been developing and producing medicines to improve people’s lives
for more than a century. We are a global leader in generic and
innovative medicines with a portfolio consisting of over 3,500
products in nearly every therapeutic area. Around 200 million
people around the world take a Teva medicine every day and are
served by one of the largest and most complex supply chains in the
pharmaceutical industry. Along with our established presence in
generics, we have significant innovative medicines research and
operations supporting our growing portfolio of innovative medicines
and biopharmaceutical products. Learn more at
www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This document and the conference call may contain
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, which are based on
management’s current beliefs and expectations and are subject to
substantial risks and uncertainties, both known and unknown, that
could cause our future results, performance, or achievements to
differ significantly from that expressed or implied by such
forward-looking statements. Important factors that could cause or
contribute to such differences include risks relating to: our
ability to successfully compete in the marketplace; our substantial
indebtedness; our business and operations in general including the
impact of global economic conditions and other macroeconomic
developments and the governmental and societal responses thereto;
compliance, regulatory and litigation matters; other financial and
economic risks; and other factors discussed in our Quarterly Report
on Form 10-Q for the third quarter of 2023 and in our Annual Report
on Form 10-K for the year ended December 31, 2022, including in the
sections captioned “Risk Factors.” Forward-looking statements speak
only as of the date on which they are made, and we assume no
obligation to update or revise any forward-looking statements or
other information contained herein, whether as a result of new
information, future events or otherwise. You are cautioned not to
put undue reliance on these forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231120252274/en/
IR Ran Meir +1 (215) 591-8912
Yael Ashman +972 (3) 914 8262
Sanjeev Sharma +1 (973) 658 2700
PR Kelley Dougherty +1 (973) 832-2810
Eden Klein +972 (3) 906 2645
Teva Pharmaceutical Indu... (NYSE:TEVA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024